Back to top

crispr: Archive

Zacks Equity Research

Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?

Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.

REGNPositive Net Change SNYNegative Net Change RHHBYPositive Net Change BAYRYNo Net Change

Zacks Equity Research

Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy Therapy

Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.

SNYNegative Net Change VRTXPositive Net Change CRSPNegative Net Change